Compare Halliburton Company (HAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs State Street SPDR S&P Biotech ETF — how do they compare? Halliburton Company trades at $33.78 (market cap $28.03B), while State Street SPDR S&P Biotech ETF trades at $158.13. The key difference: Halliburton Company pays a 2.02% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Halliburton Company nearer its low. Which is the better fit depends on your goals.
| HAL | XBI | |
|---|---|---|
Market Cap | $28.03B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $42.98 | $164.28 |
52-Week Low | $20.50 | $85.16 |
Enterprise Value | $34.18B | — |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
